ASPREE Trial: Aspirin in Healthy Elderly
New England Journal of Medicine (2018)
No CV benefit with 100mg aspirin in healthy elderly (≥70); increased major hemorrhage, narrowing primary prevention indications.
Aspirin (Low-Dose)
Oral enteric-coated tablet (81mg)Available in all 50 statesMarketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
heart
Aspirin (Low-Dose)Aspirin (Low-Dose)
Irreversible COX-1 inhibitor at low doses providing antiplatelet effects for ASCVD secondary prevention. Primary prevention role narrowed by ARRIVE, ASPREE, and ASCEND trials showing modest benefit vs bleeding risk.
Proven secondary prevention of MI and stroke
Inexpensive and widely available
Once-daily dosing
Decades of evidence
No commitment · HSA/FSA eligibleNo commitment · HSA/FSA eligible
How it works
Mechanism of action
Irreversibly acetylates COX-1 in platelets, blocking thromboxane A2 synthesis for the platelet's entire 7 to 10 day lifespan. Reduces platelet aggregation and thrombus formation.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
Clinical evidence
The research behind Aspirin (Low-Dose).
Safety profile
Monitoring & safety information.
Commonly reported side effects
- GI upset
- Easy bruising
- Dyspepsia
Less common but serious risks
- GI bleeding (dose-dependent)
- Hemorrhagic stroke
- Hypersensitivity/anaphylaxis
- Reye syndrome (children)
Generally not appropriate for
- Active GI bleeding
- Aspirin allergy
- Severe bleeding disorders
- Third trimester pregnancy
Typical monitoring
- GI symptom assessment
- Signs of bleeding
- CBC if prolonged use
FAQ
Quick answers.
Irreversible COX-1 inhibitor at low doses providing antiplatelet effects for ASCVD secondary prevention. Primary prevention role narrowed by ARRIVE, ASPREE, and ASCEND trials showing modest benefit vs bleeding risk.
Proven secondary prevention of MI and stroke. Inexpensive and widely available. Once-daily dosing. Decades of evidence.
Common side effects include: gi upset, easy bruising, dyspepsia. Most side effects are dose-dependent and may resolve with continued use or dose adjustment.
Irreversible COX-1 inhibitor at low doses providing antiplatelet effects for ASCVD secondary prevention. Primary prevention role narrowed by ARRIVE, ASPREE, and ASCEND trials showing modest benefit vs bleeding risk.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.